(ICLR) ICON - Ratings and Ratios
Exchange: NASDAQ •
Country: Ireland •
Currency: USD •
Type: Common Stock •
ISIN: IE0005711209
Clinical Research, Laboratory Services, Trial Management, Consulting
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 39.9% |
| Value at Risk 5%th | 56.7% |
| Relative Tail Risk | -13.66% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.17 |
| Alpha | -26.40 |
| CAGR/Max DD | -0.02 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.590 |
| Beta | 0.883 |
| Beta Downside | 1.001 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.43% |
| Mean DD | 22.63% |
| Median DD | 12.71% |
Description: ICLR ICON October 31, 2025
ICON Public Limited (NASDAQ: ICLR) is a Dublin-based contract research organization that delivers end-to-end outsourced development and commercialization services for pharma, biotech, and medical-device clients across Europe, the United States, and globally. Its portfolio spans the full clinical-trial lifecycle-from early-stage compound selection through Phase I-IV studies, peri- and post-approval data solutions, and decentralized/hybrid trial execution-plus laboratory, biomarker, vaccine, and GMP manufacturing capabilities.
In FY 2023 the company reported revenue of roughly **$2.9 billion**, a **~9 % year-over-year increase** driven primarily by higher demand for decentralized trial platforms and a growing backlog of multi-phase studies. Operating margin hovered around **10 %**, reflecting continued investment in digital trial infrastructure. The global CRO market is projected to grow at a **CAGR of 7 % through 2028**, propelled by rising R&D spend in the biotech sector, tighter timelines for drug approvals, and regulatory incentives for real-world evidence-factors that underpin ICON’s growth outlook.
For a deeper, data-driven valuation of ICON, you might explore the analytics on ValueRay, which aggregates peer-adjusted multiples and cash-flow forecasts to help assess the company’s relative upside.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (599.5m TTM) > 0 and > 6% of Revenue (6% = 486.2m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -1.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2.34% (prev 11.56%; Δ -9.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.18b > Net Income 599.5m (YES >=105%, WARN >=100%) |
| Net Debt (3.10b) to EBITDA (1.18b) ratio: 2.63 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (78.1m) change vs 12m ago -6.43% (target <= -2.0% for YES) |
| Gross Margin 26.85% (prev 29.58%; Δ -2.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.06% (prev 48.26%; Δ -0.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.96 (EBITDA TTM 1.18b / Interest Expense TTM 199.4m) >= 6 (WARN >= 3) |
Altman Z'' 1.17
| (A) 0.01 = (Total Current Assets 3.41b - Total Current Liabilities 3.22b) / Total Assets 16.51b |
| (B) 0.14 = Retained Earnings (Balance) 2.31b / Total Assets 16.51b |
| (C) 0.05 = EBIT TTM 790.0m / Avg Total Assets 16.86b |
| (D) 0.31 = Book Value of Equity 2.23b / Total Liabilities 7.17b |
| Total Rating: 1.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.63
| 1. Piotroski 5.50pt |
| 2. FCF Yield 5.69% |
| 3. FCF Margin 12.29% |
| 4. Debt/Equity 0.38 |
| 5. Debt/Ebitda 2.63 |
| 6. ROIC - WACC (= -7.07)% |
| 7. RoE 6.32% |
| 8. Rev. Trend 72.89% |
| 9. EPS Trend 76.32% |
What is the price of ICLR shares?
As of December 08, 2025, the stock is trading at USD 185.87 with a total of 905,324 shares traded.
Over the past week, the price has changed by +3.43%, over one month by +16.80%, over three months by +4.53% and over the past year by -15.22%.
Over the past week, the price has changed by +3.43%, over one month by +16.80%, over three months by +4.53% and over the past year by -15.22%.
Is ICLR a buy, sell or hold?
ICON has received a consensus analysts rating of 4.29.
Therefore, it is recommended to buy ICLR.
- Strong Buy: 11
- Buy: 0
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ICLR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 206.2 | 10.9% |
| Analysts Target Price | 206.2 | 10.9% |
| ValueRay Target Price | 183.4 | -1.3% |
ICLR Fundamental Data Overview December 02, 2025
Market Cap USD = 14.39b (14.39b USD * 1.0 USD.USD)
P/E Trailing = 24.9326
P/E Forward = 13.5685
P/S = 1.7757
P/B = 1.5133
P/EG = 1.4436
Beta = 1.255
Revenue TTM = 8.10b USD
EBIT TTM = 790.0m USD
EBITDA TTM = 1.18b USD
Long Term Debt = 2.88b USD (from longTermDebt, last quarter)
Short Term Debt = 567.9m USD (from shortTermDebt, last quarter)
Debt = 3.57b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.10b USD (from netDebt column, last quarter)
Enterprise Value = 17.49b USD (14.39b + Debt 3.57b - CCE 468.9m)
Interest Coverage Ratio = 3.96 (Ebit TTM 790.0m / Interest Expense TTM 199.4m)
FCF Yield = 5.69% (FCF TTM 995.8m / Enterprise Value 17.49b)
FCF Margin = 12.29% (FCF TTM 995.8m / Revenue TTM 8.10b)
Net Margin = 7.40% (Net Income TTM 599.5m / Revenue TTM 8.10b)
Gross Margin = 26.85% ((Revenue TTM 8.10b - Cost of Revenue TTM 5.93b) / Revenue TTM)
Gross Margin QoQ = 22.32% (prev 27.84%)
Tobins Q-Ratio = 1.06 (Enterprise Value 17.49b / Total Assets 16.51b)
Interest Expense / Debt = 1.41% (Interest Expense 50.2m / Debt 3.57b)
Taxrate = 93.82% (35.7m / 38.1m)
NOPAT = 48.8m (EBIT 790.0m * (1 - 93.82%))
Current Ratio = 1.06 (Total Current Assets 3.41b / Total Current Liabilities 3.22b)
Debt / Equity = 0.38 (Debt 3.57b / totalStockholderEquity, last quarter 9.33b)
Debt / EBITDA = 2.63 (Net Debt 3.10b / EBITDA 1.18b)
Debt / FCF = 3.12 (Net Debt 3.10b / FCF TTM 995.8m)
Total Stockholder Equity = 9.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.63% (Net Income 599.5m / Total Assets 16.51b)
RoE = 6.32% (Net Income TTM 599.5m / Total Stockholder Equity 9.48b)
RoCE = 6.39% (EBIT 790.0m / Capital Employed (Equity 9.48b + L.T.Debt 2.88b))
RoIC = 0.38% (NOPAT 48.8m / Invested Capital 12.90b)
WACC = 7.44% (E(14.39b)/V(17.96b) * Re(9.27%) + D(3.57b)/V(17.96b) * Rd(1.41%) * (1-Tc(0.94)))
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.07%
[DCF Debug] Terminal Value 72.05% ; FCFE base≈1.09b ; Y1≈980.1m ; Y5≈842.0m
Fair Price DCF = 161.4 (DCF Value 12.32b / Shares Outstanding 76.4m; 5y FCF grow -12.41% → 3.0% )
EPS Correlation: 76.32 | EPS CAGR: 6.32% | SUE: -0.05 | # QB: 0
Revenue Correlation: 72.89 | Revenue CAGR: 2.17% | SUE: 1.53 | # QB: 2
EPS next Quarter (2026-03-31): EPS=3.26 | Chg30d=-0.087 | Revisions Net=-5 | Analysts=11
EPS next Year (2026-12-31): EPS=13.57 | Chg30d=-0.442 | Revisions Net=-16 | Growth EPS=+3.7% | Growth Revenue=+0.7%
P/E Trailing = 24.9326
P/E Forward = 13.5685
P/S = 1.7757
P/B = 1.5133
P/EG = 1.4436
Beta = 1.255
Revenue TTM = 8.10b USD
EBIT TTM = 790.0m USD
EBITDA TTM = 1.18b USD
Long Term Debt = 2.88b USD (from longTermDebt, last quarter)
Short Term Debt = 567.9m USD (from shortTermDebt, last quarter)
Debt = 3.57b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.10b USD (from netDebt column, last quarter)
Enterprise Value = 17.49b USD (14.39b + Debt 3.57b - CCE 468.9m)
Interest Coverage Ratio = 3.96 (Ebit TTM 790.0m / Interest Expense TTM 199.4m)
FCF Yield = 5.69% (FCF TTM 995.8m / Enterprise Value 17.49b)
FCF Margin = 12.29% (FCF TTM 995.8m / Revenue TTM 8.10b)
Net Margin = 7.40% (Net Income TTM 599.5m / Revenue TTM 8.10b)
Gross Margin = 26.85% ((Revenue TTM 8.10b - Cost of Revenue TTM 5.93b) / Revenue TTM)
Gross Margin QoQ = 22.32% (prev 27.84%)
Tobins Q-Ratio = 1.06 (Enterprise Value 17.49b / Total Assets 16.51b)
Interest Expense / Debt = 1.41% (Interest Expense 50.2m / Debt 3.57b)
Taxrate = 93.82% (35.7m / 38.1m)
NOPAT = 48.8m (EBIT 790.0m * (1 - 93.82%))
Current Ratio = 1.06 (Total Current Assets 3.41b / Total Current Liabilities 3.22b)
Debt / Equity = 0.38 (Debt 3.57b / totalStockholderEquity, last quarter 9.33b)
Debt / EBITDA = 2.63 (Net Debt 3.10b / EBITDA 1.18b)
Debt / FCF = 3.12 (Net Debt 3.10b / FCF TTM 995.8m)
Total Stockholder Equity = 9.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.63% (Net Income 599.5m / Total Assets 16.51b)
RoE = 6.32% (Net Income TTM 599.5m / Total Stockholder Equity 9.48b)
RoCE = 6.39% (EBIT 790.0m / Capital Employed (Equity 9.48b + L.T.Debt 2.88b))
RoIC = 0.38% (NOPAT 48.8m / Invested Capital 12.90b)
WACC = 7.44% (E(14.39b)/V(17.96b) * Re(9.27%) + D(3.57b)/V(17.96b) * Rd(1.41%) * (1-Tc(0.94)))
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.07%
[DCF Debug] Terminal Value 72.05% ; FCFE base≈1.09b ; Y1≈980.1m ; Y5≈842.0m
Fair Price DCF = 161.4 (DCF Value 12.32b / Shares Outstanding 76.4m; 5y FCF grow -12.41% → 3.0% )
EPS Correlation: 76.32 | EPS CAGR: 6.32% | SUE: -0.05 | # QB: 0
Revenue Correlation: 72.89 | Revenue CAGR: 2.17% | SUE: 1.53 | # QB: 2
EPS next Quarter (2026-03-31): EPS=3.26 | Chg30d=-0.087 | Revisions Net=-5 | Analysts=11
EPS next Year (2026-12-31): EPS=13.57 | Chg30d=-0.442 | Revisions Net=-16 | Growth EPS=+3.7% | Growth Revenue=+0.7%
Additional Sources for ICLR Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle